BRPI0804070A2 - usos do domìnio intracitoplasmático da proteìna da quinase de linfoma anaplástico e de uma molécula de ácido nucleico, e, produto - Google Patents

usos do domìnio intracitoplasmático da proteìna da quinase de linfoma anaplástico e de uma molécula de ácido nucleico, e, produto

Info

Publication number
BRPI0804070A2
BRPI0804070A2 BRPI0804070-2A BRPI0804070A BRPI0804070A2 BR PI0804070 A2 BRPI0804070 A2 BR PI0804070A2 BR PI0804070 A BRPI0804070 A BR PI0804070A BR PI0804070 A2 BRPI0804070 A2 BR PI0804070A2
Authority
BR
Brazil
Prior art keywords
nucleic acid
anaplastic lymphoma
lymphoma kinase
product
acid molecule
Prior art date
Application number
BRPI0804070-2A
Other languages
English (en)
Inventor
Roberto Chiarle
Giorgio Inghirami
Guido Forni
Original Assignee
Roberto Chiarle
Giorgio Inghirami
Guido Forni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Chiarle, Giorgio Inghirami, Guido Forni filed Critical Roberto Chiarle
Publication of BRPI0804070A2 publication Critical patent/BRPI0804070A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

USOS DO DOMìNIO INTRACITOPLASMáTICO DA PROTEìNA DA QUINASE DE LINFOMA ANAPLáSTICO E DE UMA MOLéCULA DE áCIDO NUCLEICO, E, PRODUTO. Uso do domínio intracitoplasmático da proteína da Quinase de Linfoma Anaplástico (ALK) e/ou uma molécula de ácido nucleico que codifica o domínio intracitoplasmático da proteína da Quinase de Linfoma Anaplástico (ALK), de qualquer espécie, para a preparação de um medicamento, preferivelmente uma vacina, para o tratamento e/ou prevenção de um tumor em um paciente, preferivelmente um linfoma.
BRPI0804070-2A 2007-09-28 2008-09-26 usos do domìnio intracitoplasmático da proteìna da quinase de linfoma anaplástico e de uma molécula de ácido nucleico, e, produto BRPI0804070A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96041407P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
BRPI0804070A2 true BRPI0804070A2 (pt) 2009-09-29

Family

ID=40283936

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0804070-2A BRPI0804070A2 (pt) 2007-09-28 2008-09-26 usos do domìnio intracitoplasmático da proteìna da quinase de linfoma anaplástico e de uma molécula de ácido nucleico, e, produto

Country Status (5)

Country Link
US (2) US8980287B2 (pt)
EP (1) EP2042191B1 (pt)
BR (1) BRPI0804070A2 (pt)
CA (1) CA2640655A1 (pt)
IL (1) IL194388A0 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383793B2 (en) * 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
CA2945324A1 (en) * 2014-04-10 2015-10-15 Memorial Sloan-Kettering Cancer Center A novel isoform of anaplastic lymphoma kinase and its uses
EP3407871A4 (en) 2016-01-29 2019-12-18 Vedantra Pharmaceuticals Inc. ALK POLYPEPTIDES AND METHOD FOR USE THEREOF
US20230020894A1 (en) * 2019-09-18 2023-01-19 Children's Medical Center Corporation An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2002042232A1 (ja) 2000-11-22 2004-03-25 旭硝子株式会社 カラー陰極線管およびカラー陰極線管用ガラスフリット
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides

Also Published As

Publication number Publication date
US9650614B2 (en) 2017-05-16
IL194388A0 (en) 2011-08-01
US20150232820A1 (en) 2015-08-20
EP2042191B1 (en) 2013-01-02
US8980287B2 (en) 2015-03-17
CA2640655A1 (en) 2009-03-28
EP2042191A1 (en) 2009-04-01
US20090118216A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
AR066395A1 (es) Reovirus que tienen secuencias modificadas
BRPI0916235A2 (pt) composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv
BRPI0920261A8 (pt) Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
BR112015025711A8 (pt) uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
BRPI0817503B8 (pt) derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
BRPI0622054B8 (pt) composto e composição farmacêutica
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112014018910A8 (pt) Produto farmacêutico , kit, uso de vemurafenibe, produtos, métodos, composições e usos inovadores
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
MY166032A (en) Benzoxazole kinase inhibitors and methods of use
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
CL2008002381A1 (es) Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer.
BR112015010059A2 (pt) terapia adjuvante com inibidor da quinase da família tec
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
IL228952A0 (en) Pharmaceutical compositions comprising ferric citrate for reducing serum phosphate levels, and use thereof for the preparation of medicaments for treating or ameliorating calcium-associated disorders
BRPI0418029B8 (pt) formulação farmacêutica líquida, estável, adequada para administração parentérica que compreende um anticorpo agonista de cd40
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: ANULADA A EXIGENCIA PUBLICADA NA RPI 2004 DE 02/06/2009, POR MOTIVO DE A MESMA TER SIDO INDEVIDA.

B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 3A ANUIDADE.